Open Payments

The Moses H. Cone Memorial Hospital

Type
Teaching hospital
Where
GREENSBORO, NC
Medicare CCN
340091
Received
$808,954 in 181 records, 2025 ($91,525 general, $717,429 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment61$91,525
2025Research payment120$717,429

By company

CompanyRecordsAmountYears
Edwards Lifesciences Corporation8$156,8262025
Amgen Inc.4$144,5062025
Ionis Pharmaceuticals, Inc.10$102,7972025
Medtronic, Inc.13$101,7972025
Gilead Sciences, Inc.20$52,1422025
Insulet Corporation29$48,9752025
Janssen Research & Development, LLC11$43,4932025
Abbott Laboratories24$34,4152025
HEARTFLOW, INC.12$22,6002025
Alnylam Pharmaceuticals Inc.7$21,5882025
ABBVIE INC.1$18,0002025
E.R. Squibb & Sons, L.L.C.2$15,7602025
CVRx, Inc.5$15,1622025
Novartis Pharmaceuticals Corporation1$10,7502025
PFIZER INC.22$7,8822025
Neurocrine BioSciences, Inc.1$3,0002025
Novo Nordisk Inc1$2,5002025
Tandem Diabetes Care, Inc.5$1,8002025
Immunocore Limited1$1,7002025
Merck Sharp & Dohme LLC1$1,7002025
Genentech USA, Inc.1$1,0002025
AstraZeneca UK Limited1$4462025
Siemens Medical Solutions USA, Inc.1$1112025

By nature of payment

NatureRecordsAmount
Research payment120$717,429
Compensation for services other than consulting, including serving as faculty or as a speaker at a v34$50,775
Long term medical supply or device loan19$28,044
Space rental or facility fees (teaching hospital only)7$12,595
Debt forgiveness1$111

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Siemens Medical Solutions USA, Inc.$111Debt forgivenessIn-kind items and services2025
2025-12-23CVRx, Inc.$1,375Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-12-22Medtronic, Inc.$43,927Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsPrevail Global2025
2025-12-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-18PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-12-17Insulet Corporation$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-12-15Janssen Research & Development, LLC$8,522Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-12-11Edwards Lifesciences Corporation$4,664Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-12-09Gilead Sciences, Inc.$1,605Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-12-09Alnylam Pharmaceuticals Inc.$995Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMVUTTRA Drug, Genetic Disease2025
2025-12-05Edwards Lifesciences Corporation$26,577Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-12-04Abbott Laboratories$3,078Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-12-04Abbott Laboratories$342Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-12-01Alnylam Pharmaceuticals Inc.$2,000Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2025
2025-12-01Alnylam Pharmaceuticals Inc.$1,800Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2025
2025-12-01Alnylam Pharmaceuticals Inc.$1,000Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2025
2025-12-01Alnylam Pharmaceuticals Inc.$521Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2025
2025-11-25Insulet Corporation$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-11-24Ionis Pharmaceuticals, Inc.$49,678Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-11-24Ionis Pharmaceuticals, Inc.$3,060Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-11-24Ionis Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-11-24Ionis Pharmaceuticals, Inc.$1,000Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-11-24Ionis Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-11-24Abbott Laboratories$414Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartNCT03309332--AMPLATZER PFO Occluder Post Approval Study2025
2025-11-24Ionis Pharmaceuticals, Inc.$262Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS52025
2025-11-21Janssen Research & Development, LLC$3,044Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-11-12Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-11-10Abbott Laboratories$2,736Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-11-05Medtronic, Inc.$16,250Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-11-05Medtronic, Inc.$5,000Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-11-05Insulet Corporation$2,750Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-11-05Medtronic, Inc.$450Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-10-31Ionis Pharmaceuticals, Inc.$20,809Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-10-29Ionis Pharmaceuticals, Inc.$10,885Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS152025
2025-10-28CVRx, Inc.$1,400Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-10-28Gilead Sciences, Inc.$730Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-10-24Medtronic, Inc.$2,400Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-10-24Medtronic, Inc.$312Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-10-23Medtronic, Inc.$2,390Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-10-22Janssen Research & Development, LLC$4,355Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-10-22Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-10-21Gilead Sciences, Inc.$1,920Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-10-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-10-17PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-10-16HEARTFLOW, INC.$1,800Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-10-16HEARTFLOW, INC.$1,600Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-10-15Edwards Lifesciences Corporation$15,971Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-10-14Gilead Sciences, Inc.$1,120Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-10-14HEARTFLOW, INC.$1,000Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-10-14HEARTFLOW, INC.$800Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-10-06Abbott Laboratories$4,104Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-10-06Medtronic, Inc.$269Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-10-02Edwards Lifesciences Corporation$16,510Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-10-02PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-10-02PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-10-02PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-09-23Gilead Sciences, Inc.$6,650Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-09-23Gilead Sciences, Inc.$1,794Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-09-19Janssen Research & Development, LLC$3,069Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-09-15Edwards Lifesciences Corporation$22,618Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-09-10Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-09-09Gilead Sciences, Inc.$900Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-09-03Insulet Corporation$925Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-09-02Medtronic, Inc.$5,006Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-08-26Neurocrine BioSciences, Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentINGREZZA Drug, Neuropsychiatry2025
2025-08-26Amgen Inc.$2,871Research paymentCash or cash equivalentA Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiov2025
2025-08-25Janssen Research & Development, LLC$2,312Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-08-22Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-08-22Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-08-22Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-08-22Abbott Laboratories$684Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-08-22Abbott Laboratories$684Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-08-20Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-08-20AstraZeneca UK Limited$446Research paymentCash or cash equivalentTruqap Drug, OncologyA Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib Fulvestrant Versus Placebo F2025
2025-08-20Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-08-19Gilead Sciences, Inc.$1,920Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-08-13Insulet Corporation$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-08-11Abbott Laboratories$883Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartNCT03309332--AMPLATZER PFO Occluder Post Approval Study2025
2025-08-06Ionis Pharmaceuticals, Inc.$14,063Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS152025
2025-08-06Ionis Pharmaceuticals, Inc.$1,039Research paymentCash or cash equivalentOLEZARSEN Drug, CARDIOLOGYIS354CS92025
2025-08-01Medtronic, Inc.$13,000Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsPrevail Global2025
2025-07-31Edwards Lifesciences Corporation$5,392Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-07-29CVRx, Inc.$1,375Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-07-25Edwards Lifesciences Corporation$17,982Research paymentCash or cash equivalentThe PROGRESS Trial 2021-012025
2025-07-23Janssen Research & Development, LLC$4,635Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-07-22Gilead Sciences, Inc.$8,148Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-07-22Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-07-20Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-07-20Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-07-16Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-07-15Insulet Corporation$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-07-09Medtronic, Inc.$4,908Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-07-07HEARTFLOW, INC.$800Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-07-07HEARTFLOW, INC.$800Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-07-01Insulet Corporation$2,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-06-25Amgen Inc.$9,830Research paymentCash or cash equivalentThe African American Heart Study: A Real-World Data Study of Atherosclerotic Cardiovascular Risk in African American and2025
2025-06-24Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-06-23PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-06-20Janssen Research & Development, LLC$3,942Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-06-10Insulet Corporation$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-06-09E.R. Squibb & Sons, L.L.C.$14,060Research paymentCash or cash equivalentCAMZYOS Drug, CardiovascularShared Decision Support Intervention in the Use of Cardiac Myosin Inhibition- A Pilot Program2025
2025-06-05HEARTFLOW, INC.$2,600Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-06-04Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-06-04Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-05-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-30PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-05-27HEARTFLOW, INC.$2,600Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-05-27Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-21Abbott Laboratories$924Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartNCT03309332--AMPLATZER PFO Occluder Post Approval Study2025
2025-05-20Gilead Sciences, Inc.$2,388Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-05-20Gilead Sciences, Inc.$925Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-05-20Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-16Janssen Research & Development, LLC$1,226Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-05-14Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-05-13Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-06Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-02Merck Sharp & Dohme LLC$1,700Space rental or facility fees (teaching hospital only)Cash or cash equivalentKEYTRUDA Biological, ONCOLOGY2025
2025-05-02Insulet Corporation$1,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-05-01Edwards Lifesciences Corporation$47,109Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2025
2025-05-01CVRx, Inc.$1,362Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-04-29HEARTFLOW, INC.$2,600Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-04-29HEARTFLOW, INC.$2,600Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-04-29PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-04-24Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-04-23Janssen Research & Development, LLC$5,038Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-04-22Gilead Sciences, Inc.$7,402Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-04-22Insulet Corporation$375Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-04-16Alnylam Pharmaceuticals Inc.$992Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2025
2025-04-15Gilead Sciences, Inc.$950Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-04-11Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-04-10Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-04-08Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-04-03Novartis Pharmaceuticals Corporation$10,750Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesA randomized, controlled, multicenter, open-label trial comparing a post-discharge care pathway involving aggressive LDL2025
2025-04-01Gilead Sciences, Inc.$500Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-03-31Medtronic, Inc.$1Research paymentIn-kind items and servicesREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-03-28Genentech USA, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentXolair Biological, Immunology2025
2025-03-25Medtronic, Inc.$7,884Research paymentCash or cash equivalentREVEAL LINQ Device, Cardiac Diagnostics and MonitoringALLEVIATE-HF2025
2025-03-18Gilead Sciences, Inc.$1,310Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-03-17Janssen Research & Development, LLC$1,716Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-03-12Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-03-12PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-03-12PFIZER INC.$54Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-03-07ABBVIE INC.$18,000Research paymentCash or cash equivalentM23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination2025
2025-03-04Gilead Sciences, Inc.$700Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-03-03Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-02-25E.R. Squibb & Sons, L.L.C.$1,700Space rental or facility fees (teaching hospital only)Cash or cash equivalentOPDIVO Biological, Oncology2025
2025-02-21Alnylam Pharmaceuticals Inc.$14,279Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2025
2025-02-19Gilead Sciences, Inc.$3,310Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-02-19Immunocore Limited$1,700Space rental or facility fees (teaching hospital only)Cash or cash equivalentKIMMTRAK Drug, Oncology2025
2025-02-17Abbott Laboratories$3,650Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartNCT03309332--AMPLATZER PFO Occluder Post Approval Study2025
2025-02-14Abbott Laboratories$500Research paymentCash or cash equivalentAMPLATZER TALISMAN Device, Structural HeartNCT03309332--AMPLATZER PFO Occluder Post Approval Study2025
2025-02-13Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-02-13Abbott Laboratories$1,368Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-02-07HEARTFLOW, INC.$2,000Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025
2025-02-05Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-30Amgen Inc.$11,828Research paymentCash or cash equivalentREPATHA Biological, CardiovascularA Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiova2025
2025-01-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-01-30PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2025
2025-01-29Insulet Corporation$18,525Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-29Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-29Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2025
2025-01-28Gilead Sciences, Inc.$950Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-01-27Novo Nordisk Inc$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-01-23Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-22Gilead Sciences, Inc.$7,470Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-01-22Janssen Research & Development, LLC$5,634Research paymentCash or cash equivalentA Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-01-16Insulet Corporation$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-16Abbott Laboratories$684Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-01-16Abbott Laboratories$684Long term medical supply or device loanIn-kind items and servicesFREESTYLE LIBRE Device, Diabetes Care2025
2025-01-15CVRx, Inc.$9,650Research paymentCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-01-14Amgen Inc.$119,976Research paymentIn-kind items and servicesA Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascu2025
2025-01-08Insulet Corporation$550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOMNIPOD Device, Insulin Pump2025
2025-01-07Gilead Sciences, Inc.$1,450Research paymentCash or cash equivalentYeztugo Drug, HIVA Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly 2025
2025-01-03HEARTFLOW, INC.$3,400Research paymentCash or cash equivalentFFRct Device, Coronary459 DECIDE Registry2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Guilford CountyGreensboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Greensboro, NC, county Guilford County, NC, state North Carolina; placed by its city name.

MeasurePlace (city or town)
Greensboro, NC
County
Guilford County, NC
State
North Carolina
Population B01003301,198547,94010,730,404
Population, 2020 census P1299,035541,29910,439,388
Median age B0100234.337.539.1
Under 18 B0100121.7%22.0%21.8%
65 and over B0100114.4%15.9%17.2%
Households B11001123,984219,7184,282,345
Foreign born B0500212.7%11.8%9.1%
Median household income B19013$61,515$68,642$72,388
Median family income B19113$80,585$88,156$90,290
Per capita income B19301$37,531$39,376$41,385
Poverty rate B1700117.0%14.6%13.0%
Unemployment rate B230255.1%4.6%4.7%
Civilian labor force B23025158,568282,3625,336,863
Mean commute (minutes) B0801321.722.025.1
Bachelor's degree or higher B1500341.0%39.0%35.7%
Housing units B25001135,665238,0324,895,668
Owner-occupied B2500350.5%59.9%66.6%
Renters B2500349.5%40.1%33.4%
Median home value B25077$244,800$259,900$288,900
Median gross rent B25064$1,172$1,163$1,228
White, not Hispanic B0300238.1%46.0%60.0%
Black B0300241.0%33.5%20.0%
Hispanic or Latino B0300210.5%10.1%11.3%
Asian B030025.2%5.4%3.3%
American Indian and Alaska Native B030020.2%0.1%0.8%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Greensboro, NC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.